<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="cas70214" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2682</journal-id><journal-id journal-id-type="pmc-domain">cas</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12775561</article-id><article-id pub-id-type="pmcid-ver">PMC12775561.1</article-id><article-id pub-id-type="pmcaid">12775561</article-id><article-id pub-id-type="pmcaiid">12775561</article-id><article-id pub-id-type="pmid">41128349</article-id><article-id pub-id-type="doi">10.1111/cas.70214</article-id><article-id pub-id-type="publisher-id">CAS70214</article-id><article-id pub-id-type="other">CAS-OA-0959-2025.R1</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>ORIGINAL ARTICLE</subject><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Comparative Analysis of a Dual <styled-content style="fixed-case" toggle="no">DNA</styled-content>&#8211;<styled-content style="fixed-case" toggle="no">RNA</styled-content> Panel and a <styled-content style="fixed-case" toggle="no">DNA</styled-content>&#8208;Only Panel for Sarcoma: Real&#8208;World Data From a Nationwide Genomic Database</article-title></title-group><contrib-group><contrib id="cas70214-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Nakata</surname><given-names initials="E">Eiji</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5971-4142</contrib-id><xref rid="cas70214-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>eijinakata8522@yahoo.co.jp</email></address></contrib><contrib id="cas70214-cr-0002" contrib-type="author"><name name-style="western"><surname>Ninomiya</surname><given-names initials="K">Kiichiro</given-names></name><xref rid="cas70214-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cas70214-cr-0003" contrib-type="author"><name name-style="western"><surname>Osone</surname><given-names initials="T">Tatsunori</given-names></name><xref rid="cas70214-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cas70214-cr-0004" contrib-type="author"><name name-style="western"><surname>Ennishi</surname><given-names initials="D">Daisuke</given-names></name><xref rid="cas70214-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cas70214-cr-0005" contrib-type="author"><name name-style="western"><surname>Tomida</surname><given-names initials="S">Shuta</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3786-936X</contrib-id><xref rid="cas70214-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cas70214-cr-0006" contrib-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names initials="T">Tomohiro</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4257-9180</contrib-id><xref rid="cas70214-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cas70214-cr-0007" contrib-type="author"><name name-style="western"><surname>Kunisada</surname><given-names initials="T">Toshiyuki</given-names></name><xref rid="cas70214-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cas70214-cr-0008" contrib-type="author"><name name-style="western"><surname>Futagawa</surname><given-names initials="M">Mashu</given-names></name><xref rid="cas70214-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cas70214-cr-0009" contrib-type="author"><name name-style="western"><surname>Hirasawa</surname><given-names initials="A">Akira</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4124-5488</contrib-id><xref rid="cas70214-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cas70214-cr-0010" contrib-type="author"><name name-style="western"><surname>Toyooka</surname><given-names initials="S">Shinichi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7588-6745</contrib-id><xref rid="cas70214-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cas70214-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cas70214-cr-0011" contrib-type="author"><name name-style="western"><surname>Ozaki</surname><given-names initials="T">Toshifumi</given-names></name><xref rid="cas70214-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cas70214-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Orthopaedic Surgery</named-content>
<institution>Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</institution>
<city>Okayama</city>
<country country="JP">Japan</country>
</aff><aff id="cas70214-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Center for Comprehensive Genomic Medicine</named-content>
<institution>Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</institution>
<city>Okayama</city>
<country country="JP">Japan</country>
</aff><aff id="cas70214-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Regenerative Science</named-content>
<institution>Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</institution>
<city>Okayama</city>
<country country="JP">Japan</country>
</aff><aff id="cas70214-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Genomic Medicine</named-content>
<institution>Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</institution>
<city>Okayama</city>
<country country="JP">Japan</country>
</aff><aff id="cas70214-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of General Thoracic and Breast and Endocrinological Surgery</named-content>
<institution>Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</institution>
<city>Okayama</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Eiji Nakata (<email>eijinakata8522@yahoo.co.jp</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>10</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>117</volume><issue seq="140">1</issue><issue-id pub-id-type="pmc-issue-id">504369</issue-id><issue-id pub-id-type="doi">10.1111/cas.v117.1</issue-id><fpage>156</fpage><lpage>168</lpage><history><date date-type="rev-recd"><day>29</day><month>8</month><year>2025</year></date><date date-type="received"><day>13</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-08 00:25:13.130"><day>08</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">Cancer Science</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CAS-117-156.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CAS-117-156.pdf"/><abstract><title>ABSTRACT</title><p>Next&#8208;generation sequencing&#8208;based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor&#8208;only DNA panels from single institutions. In 2023, Japan introduced an insurance&#8208;covered cancer genomic profiling test&#8212;the GenMine TOP Cancer Genome Profiling System&#8212;a dual DNA&#8211;RNA panel with matched tumor&#8211;normal testing. This study evaluated its utility compared to a conventional DNA&#8208;only test (FoundationOne CDx) in managing sarcoma patients using a nationwide genetic profiling database provided by the Center for Cancer Genomics and Advanced Therapeutics. This study included 1046 patients registered between August 2023 and October 2024. The dual DNA&#8211;RNA test identified significantly more fusion genes (20.3% vs. 7.4%, <italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, <italic toggle="no">p</italic>&#8201;=&#8201;0.019) than the DNA&#8208;only test. Among patients with translocation&#8208;related sarcomas, histology&#8208;specific fusion genes were identified in 77.5% using the dual panel, compared to 40.0% with the DNA&#8208;only panel (<italic toggle="no">p</italic>&#8201;&lt;&#8201;0.001). In non&#8208;gastrointestinal stromal tumor sarcomas, the dual test showed a trend toward higher rates of genotype&#8208;matched therapy (4.3% vs. 2.6%, <italic toggle="no">p</italic>&#8201;=&#8201;0.25) and a significantly higher rate of molecular targeted therapy (4.3% vs. 1.5%, <italic toggle="no">p</italic>&#8201;=&#8201;0.03). Additionally, 5.7% of patients had pathogenic germline variants identified through tumor&#8211;normal matched analysis. These findings suggest that a dual DNA&#8211;RNA panel with matched tumor&#8211;normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma.</p></abstract><abstract abstract-type="graphical"><p>Dual DNA&#8211;RNA panel with matched tumor&#8211;normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma.<boxed-text position="anchor" content-type="graphic" id="cas70214-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CAS-117-156-g003.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cas70214-kwd-0001">comprehensive cancer genomic profiling (CGP)</kwd><kwd id="cas70214-kwd-0002">fusion genes</kwd><kwd id="cas70214-kwd-0003">gene alterations</kwd><kwd id="cas70214-kwd-0004">genotype&#8208;matched therapy</kwd><kwd id="cas70214-kwd-0005">potential germline variants (PGVs)</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>KAKENHI</institution><institution-id institution-id-type="doi">10.13039/501100001691</institution-id></institution-wrap></funding-source><award-id>23K08632</award-id><award-id>24K10453</award-id><award-id>24K12308</award-id><award-id>24K12332</award-id><award-id>24K12374</award-id><award-id>23K08698</award-id></award-group></funding-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="13"/><word-count count="7700"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.6 mode:remove_FC converted:07.01.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cas70214-ntgp-0001"><fn fn-type="funding" id="cas70214-note-0001"><p>
<bold>Funding:</bold> This study was supported by KAKENHI (grant no. 23K08632, 24K10453, 24K12308, 24K12332, 24K12374, 23K08698).</p></fn></fn-group></notes></front><body id="cas70214-body-0001"><def-list list-content="abbreviations" id="cas70214-dl-0001"><title>Abbreviations</title><def-item><term id="cas70214-li-0001">ACMG/AMP</term><def id="cas70214-li-0002"><p>American College of Medical Genetics and Genomics and the Association for Molecular Pathology</p></def></def-item><def-item><term id="cas70214-li-0003">C&#8208;CAT</term><def id="cas70214-li-0004"><p>center for cancer genomics and advanced therapeutics</p></def></def-item><def-item><term id="cas70214-li-0005">CGP</term><def id="cas70214-li-0006"><p>cancer genomic profiling</p></def></def-item><def-item><term id="cas70214-li-0007">CNV</term><def id="cas70214-li-0008"><p>copy number variations</p></def></def-item><def-item><term id="cas70214-li-0009">COSMIC</term><def id="cas70214-li-0010"><p>catalogue of somatic mutations in cancer</p></def></def-item><def-item><term id="cas70214-li-0011">CPS</term><def id="cas70214-li-0012"><p>cancer predisposition syndromes</p></def></def-item><def-item><term id="cas70214-li-0013">DDLS</term><def id="cas70214-li-0014"><p>dedifferentiated liposarcoma</p></def></def-item><def-item><term id="cas70214-li-0017">DFSP</term><def id="cas70214-li-0018"><p>dermatofibrosarcoma protuberans</p></def></def-item><def-item><term id="cas70214-li-0019">ES</term><def id="cas70214-li-0020"><p>ewing sarcoma</p></def></def-item><def-item><term id="cas70214-li-0021">GenMine TOP</term><def id="cas70214-li-0022"><p>GenMine Top cancer genome profiling system</p></def></def-item><def-item><term id="cas70214-li-0023">GPVs</term><def id="cas70214-li-0024"><p>germline pathogenic variants</p></def></def-item><def-item><term id="cas70214-li-0025">LMS</term><def id="cas70214-li-0026"><p>leiomyosarcoma</p></def></def-item><def-item><term id="cas70214-li-0027">MSI</term><def id="cas70214-li-0028"><p>microsatellite instability</p></def></def-item><def-item><term id="cas70214-li-0029">MSS</term><def id="cas70214-li-0030"><p>microsatellite&#8208;stable</p></def></def-item><def-item><term id="cas70214-li-0031">MTB</term><def id="cas70214-li-0032"><p>molecular tumor boards</p></def></def-item><def-item><term id="cas70214-li-0033">NCC</term><def id="cas70214-li-0034"><p>National Cancer Center</p></def></def-item><def-item><term id="cas70214-li-0035">NGS</term><def id="cas70214-li-0036"><p>next&#8208;generation sequencing</p></def></def-item><def-item><term id="cas70214-li-0037">OS</term><def id="cas70214-li-0038"><p>overall survival</p></def></def-item><def-item><term id="cas70214-li-0039">SNV</term><def id="cas70214-li-0040"><p>single nucleotide variants</p></def></def-item><def-item><term id="cas70214-li-0041">STS</term><def id="cas70214-li-0042"><p>soft tissue sarcoma</p></def></def-item><def-item><term id="cas70214-li-0043">SYNS</term><def id="cas70214-li-0044"><p>synovial sarcoma</p></def></def-item><def-item><term id="cas70214-li-0045">TMB</term><def id="cas70214-li-0046"><p>tumor mutation burden</p></def></def-item><def-item><term id="cas70214-li-0047">TRS</term><def id="cas70214-li-0048"><p>translocation&#8208;related sarcomas</p></def></def-item><def-item><term id="cas70214-li-0049">ULMS</term><def id="cas70214-li-0050"><p>uterine leiomyosarcoma</p></def></def-item><def-item><term id="cas70214-li-0051">VUS</term><def id="cas70214-li-0052"><p>variants of unknown significance</p></def></def-item></def-list><sec id="cas70214-sec-0001"><label>1</label><title>Introduction</title><p>The development of next&#8208;generation sequencing (NGS) has revealed various genetic mutations and functional pathways in different cancers [<xref rid="cas70214-bib-0001" ref-type="bibr">1</xref>, <xref rid="cas70214-bib-0002" ref-type="bibr">2</xref>]. Large&#8208;scale databases such as the Catalogue of Somatic Mutations in Cancer (COSMIC) and the AACR Project GENIE have revealed the genomic landscape and novel therapeutic targets in sarcoma [<xref rid="cas70214-bib-0003" ref-type="bibr">3</xref>, <xref rid="cas70214-bib-0004" ref-type="bibr">4</xref>]. NGS&#8208;based comprehensive cancer genomic profiling (CGP) tests are now widely implemented in clinical practice [<xref rid="cas70214-bib-0001" ref-type="bibr">1</xref>, <xref rid="cas70214-bib-0002" ref-type="bibr">2</xref>]. In Japan, CGP testing was introduced in 2019, and the Center for Cancer Genomics and Advanced Therapeutics (C&#8208;CAT) was established as a national initiative to collect real&#8208;world genomic and clinical data from cancer patients, providing valuable resources for cancer genome research [<xref rid="cas70214-bib-0005" ref-type="bibr">5</xref>, <xref rid="cas70214-bib-0006" ref-type="bibr">6</xref>, <xref rid="cas70214-bib-0007" ref-type="bibr">7</xref>, <xref rid="cas70214-bib-0008" ref-type="bibr">8</xref>, <xref rid="cas70214-bib-0009" ref-type="bibr">9</xref>, <xref rid="cas70214-bib-0010" ref-type="bibr">10</xref>]. Currently, the Japanese public health insurance system reimburses five types of CGP tests. The first four are DNA&#8208;based, capable of detecting 124&#8211;309 gene alterations and 13&#8211;36 gene rearrangements: FoundationOne CDx cancer genome profiling (F1CDx, Chugai Pharmaceutical) and OncoGuide NCC Oncopanel System (NCC Onco&#8208;panel, Sysmex Corporation, Hyogo, Japan), FoundationOne Liquid CDx cancer genome profiling (F1LCDx; Chugai Pharmaceutical, Tokyo, Japan), and Guardant360 CDx (Guardant Health, Guardant Health Inc., Redwood City, CA, USA) [<xref rid="cas70214-bib-0011" ref-type="bibr">11</xref>]. Although the identification of fusion genes is essential in certain malignancies, such as sarcomas, these panels have limitations in detecting them effectively. Recently, cancer predisposition syndromes (CPS) have gained increased recognition due to the broader use of CGP tests [<xref rid="cas70214-bib-0012" ref-type="bibr">12</xref>, <xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>]. CGP tests reportedly play a crucial role in identifying germline alterations, which are detected in 3.3%&#8211;16.7% of patients with various malignancies undergoing CGP tests in clinical settings [<xref rid="cas70214-bib-0012" ref-type="bibr">12</xref>, <xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>]. However, most CGP tests utilize tumor&#8208;only sequencing, which cannot distinguish between somatic and germline variants. This limitation may lead to either a failure to confirm pathogenic germline variants or the misclassification of germline variants as somatic, thereby missing a CPS diagnosis. To resolve the limitations of the ordinary CGP test, its development was warranted.</p><p>In 2023, an insurance&#8208;covered CGP test called the GenMine TOP Cancer Genome Profiling System (GenMineTOP) was introduced in Japan [<xref rid="cas70214-bib-0012" ref-type="bibr">12</xref>, <xref rid="cas70214-bib-0014" ref-type="bibr">14</xref>, <xref rid="cas70214-bib-0015" ref-type="bibr">15</xref>]. GenMineTOP is a novel dual DNA&#8211;RNA panel that functions as a paired tumor&#8211;normal matched test. It simultaneously integrates and analyzes DNA and RNA data, detecting 737 gene alterations through its DNA panel and identifying 455 fusion transcripts, exon&#8208;skipping events in five genes, and expression levels of 27 genes via its RNA panel [<xref rid="cas70214-bib-0010" ref-type="bibr">10</xref>, <xref rid="cas70214-bib-0011" ref-type="bibr">11</xref>, <xref rid="cas70214-bib-0012" ref-type="bibr">12</xref>, <xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>, <xref rid="cas70214-bib-0014" ref-type="bibr">14</xref>]. GenMineTOP offers several advantages over DNA&#8208;only panels. These include improved detection of gene fusions using the RNA panel, enhanced identification of potential therapeutic targets, and the ability to detect potential germline variants (PGVs), which are critical for identifying hereditary cancer predispositions. These features contribute to a more accurate diagnosis, better selection of targeted therapies, and assessment of hereditary cancer risk. The utility of GenMineTOP has been demonstrated in studies conducted under the Advanced Medical Care B program in various cancer types [<xref rid="cas70214-bib-0012" ref-type="bibr">12</xref>, <xref rid="cas70214-bib-0014" ref-type="bibr">14</xref>, <xref rid="cas70214-bib-0015" ref-type="bibr">15</xref>]. However, data on the utility of this panel in clinical settings after the implementation of insurance coverage is lacking.</p><p>Sarcomas are rare cancers, accounting for approximately 1%&#8211;2% of all malignancies [<xref rid="cas70214-bib-0016" ref-type="bibr">16</xref>]. Most sarcomas are treated with cytotoxic drugs, which show limited efficacy. Some sarcomas exhibit distinct molecular characteristics that are critical for accurate diagnosis and treatment planning. These include the <italic toggle="yes">EWSR1::FLI1</italic> fusion in Ewing sarcoma (ES), <italic toggle="yes">SYT::SSX</italic> fusion in synovial sarcoma (SYNS), and <italic toggle="yes">MDM2</italic> amplification in dedifferentiated liposarcoma (DDLS) [<xref rid="cas70214-bib-0017" ref-type="bibr">17</xref>]. Due to their rarity and heterogeneity of sarcomas, diagnostic errors are relatively common, with reported rates of up to 10.5% [<xref rid="cas70214-bib-0018" ref-type="bibr">18</xref>]. Several studies have examined the use of CGP in sarcoma [<xref rid="cas70214-bib-0018" ref-type="bibr">18</xref>, <xref rid="cas70214-bib-0019" ref-type="bibr">19</xref>, <xref rid="cas70214-bib-0020" ref-type="bibr">20</xref>, <xref rid="cas70214-bib-0021" ref-type="bibr">21</xref>, <xref rid="cas70214-bib-0022" ref-type="bibr">22</xref>, <xref rid="cas70214-bib-0023" ref-type="bibr">23</xref>, <xref rid="cas70214-bib-0024" ref-type="bibr">24</xref>], reporting that 32%&#8211;62% of patients harbor potentially actionable alterations, and 8%&#8211;16% receive therapies targeting these alterations. However, these studies primarily utilized DNA&#8208;only panels. The clinical performance of dual DNA&#8211;RNA panels, particularly in routine settings, has not yet been evaluated in patients with sarcoma. Therefore, we evaluated the clinical impact of GenMineTOP in the management of patients with sarcomas using real&#8208;world genomic data from Japan's nationwide C&#8208;CAT database.</p></sec><sec sec-type="materials-and-methods" id="cas70214-sec-0002"><label>2</label><title>Material and Methods</title><sec id="cas70214-sec-0003"><label>2.1</label><title>Study Population From the C&#8208;<styled-content style="fixed-case" toggle="no">CAT</styled-content> Database</title><p>Genomic and clinical information of patients diagnosed with sarcoma was retrieved from the C&#8208;CAT on December 27, 2024, via the C&#8208;CAT portal (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncc.go.jp/en/c_cat/use/index.html" ext-link-type="uri">https://www.ncc.go.jp/en/c_cat/use/index.html</ext-link>). The study included patients registered between August 2023 and October 2024, which corresponds to the initial period of GenMineTOP data entry into the C&#8208;CAT database. Patients with benign bone and soft tissue tumors were excluded. The information includes genetic alterations, sex, age, Eastern Cooperative Oncology Group performance status, histology, specimen type, site and collection method, treatment before and after the oncogene panel test, date of last known alive, and date of death. Histological classifications were based on the World Health Organization (WHO) classification [<xref rid="cas70214-bib-0016" ref-type="bibr">16</xref>]. Histologic subtypes were grouped into three categories according to their known genetic features: translocation&#8208;related sarcomas (TRS), which are characterized by specific reciprocal translocations resulting in oncogenic fusion transcripts; genomically complex sarcomas, which exhibit multiple, complex karyotypic abnormalities without a recurrent pattern; and other sarcomas, defined by the presence of specific oncogenic mutations or recurrent amplifications (Table&#160;<xref rid="cas70214-supitem-0004" ref-type="supplementary-material">S1</xref>) [<xref rid="cas70214-bib-0018" ref-type="bibr">18</xref>].</p></sec><sec id="cas70214-sec-0004"><label>2.2</label><title>Comprehensive Genomic Profiling Tests</title><p>Two CGP tests reimbursed by the Japanese public health insurance system were used in this study: FoundationOne CDx (F1CDx, Chugai Pharmaceutical) and GenMineTOP (GenMine, Konica Minolta REALM Inc. Tokyo, Japan) (Table&#160;<xref rid="cas70214-supitem-0005" ref-type="supplementary-material">S2</xref>). The gene lists analyzed by each CGP test are shown in Table&#160;<xref rid="cas70214-supitem-0006" ref-type="supplementary-material">S3</xref>. F1CDx evaluates 324 genes and identifies single nucleotide variants (SNV), insertions/deletions (indels), and copy number variations (CNV, including amplifications and gains) in 309 genes. It also detects fusions involving 36 genes, as well as microsatellite instability (MSI) and tumor mutation burden (TMB) [<xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>]. F1CDx is a tumor&#8208;only panel and therefore cannot distinguish between germline and somatic mutations. In contrast, GenMineTOP is a dual&#8208;panel test that integrates DNA and RNA analysis. Its DNA panel detects 737 gene alterations, including SNV, indels, and CNV (amplifications), while its RNA panel identifies 455 fusion transcripts, exon skipping events in five genes, and expression profiles of 27 genes [<xref rid="cas70214-bib-0010" ref-type="bibr">10</xref>, <xref rid="cas70214-bib-0011" ref-type="bibr">11</xref>, <xref rid="cas70214-bib-0012" ref-type="bibr">12</xref>, <xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>, <xref rid="cas70214-bib-0015" ref-type="bibr">15</xref>]. The RNA panel targets RNA isolated from formalin&#8208;fixed paraffin&#8208;embedded tumor samples, converts it into cDNA, and uses targeted probes to capture specific regions of interest. GenMineTOP reports CNVs limited to amplifications but does not detect copy number losses. Additionally, MSI status is not assessed by this panel. GenMineTOP operates as a paired tumor&#8208;normal matched test; genomic DNA is also extracted from peripheral blood samples to serve as a normal reference, allowing for the discrimination between somatic and germline variants. Among the 40 genes analyzed for germline variants are <italic toggle="yes">TP53</italic>, <italic toggle="yes">RB1</italic>, <italic toggle="yes">NF1</italic>, and <italic toggle="yes">BRCA1</italic> (Table&#160;<xref rid="cas70214-supitem-0006" ref-type="supplementary-material">S3</xref>). Germline alterations were reported as pathogenic or likely pathogenic variants if classified accordingly in the ClinVar or Ambry Genetics databases [<xref rid="cas70214-bib-0025" ref-type="bibr">25</xref>, <xref rid="cas70214-bib-0026" ref-type="bibr">26</xref>]. In addition, null variants in tumor suppressor genes were also considered germline pathogenic variants. Further technical details regarding the CGP assays and the associated bioinformatics pipelines can be found in previously published studies [<xref rid="cas70214-bib-0010" ref-type="bibr">10</xref>, <xref rid="cas70214-bib-0011" ref-type="bibr">11</xref>, <xref rid="cas70214-bib-0012" ref-type="bibr">12</xref>, <xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>, <xref rid="cas70214-bib-0015" ref-type="bibr">15</xref>].</p></sec><sec id="cas70214-sec-0005"><label>2.3</label><title>Annotation of the <styled-content style="fixed-case" toggle="no">NGS</styled-content> Results</title><p>The C&#8208;CAT was established at the National Cancer Center (NCC) to centralize genomic and clinical data from patients undergoing CGP reimbursed by public health insurance in Japan [<xref rid="cas70214-bib-0006" ref-type="bibr">6</xref>, <xref rid="cas70214-bib-0007" ref-type="bibr">7</xref>, <xref rid="cas70214-bib-0008" ref-type="bibr">8</xref>, <xref rid="cas70214-bib-0009" ref-type="bibr">9</xref>]. C&#8208;CAT constructs and maintains the Cancer Knowledge Database, a national resource that supports the interpretation of genomic data and provides clinical annotations to inform cancer treatment decisions [<xref rid="cas70214-bib-0006" ref-type="bibr">6</xref>, <xref rid="cas70214-bib-0007" ref-type="bibr">7</xref>]. For each patient, clinical information and CGP results were collected in C&#8208;CAT. The pathogenicity of each identified variant was annotated according to the C&#8208;CAT guidelines, developed through a joint consensus by the Japanese Society of Medical Oncology, the Japan Society of Clinical Oncology, and the Japanese Cancer Association [<xref rid="cas70214-bib-0009" ref-type="bibr">9</xref>]. These annotations were based on a database of genomic profiles from over 90,000 patients. Reports were generated to provide personalized treatment recommendations, tailored to each patient's genomic profile&#160;[<xref rid="cas70214-bib-0005" ref-type="bibr">5</xref>, <xref rid="cas70214-bib-0006" ref-type="bibr">6</xref>, <xref rid="cas70214-bib-0007" ref-type="bibr">7</xref>, <xref rid="cas70214-bib-0008" ref-type="bibr">8</xref>]. Genomic alterations were classified into seven evidence levels (A&#8211;F and R), as defined by the C&#8208;CAT evidence&#8208;tier system (Table&#160;<xref rid="cas70214-supitem-0007" ref-type="supplementary-material">S4</xref>) [<xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>]. C&#8208;CAT reports included details such as the evidence level for therapeutic efficacy, the availability of therapeutic agents, and relevant genotype&#8208;matched clinical trials. These reports were sent to the corresponding hospitals. All CGP test results were reviewed by institutional molecular tumor boards (MTB), also referred to as &#8220;expert panels.&#8221; These panels consisted of multidisciplinary teams including organ&#8208;specific oncologists, clinical geneticists, certified genetic counselors, pathologists, bioinformaticians, and pharmacists [<xref rid="cas70214-bib-0006" ref-type="bibr">6</xref>, <xref rid="cas70214-bib-0007" ref-type="bibr">7</xref>, <xref rid="cas70214-bib-0008" ref-type="bibr">8</xref>]. As described previously, potentially oncogenic and druggable gene alterations were defined as those classified at or above evidence level F and level D [<xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>]. Based on each patient's treatment history, clinical background, the strength and nature of the supporting evidence, and the accessibility of therapeutic agents, the expert panel determined recommendations for genotype&#8208;matched therapies. The corresponding data were then aggregated within the C&#8208;CAT system [<xref rid="cas70214-bib-0006" ref-type="bibr">6</xref>, <xref rid="cas70214-bib-0007" ref-type="bibr">7</xref>, <xref rid="cas70214-bib-0008" ref-type="bibr">8</xref>].</p></sec><sec id="cas70214-sec-0006"><label>2.4</label><title>Profiling of Genomic Alterations</title><p>SNVs, indels, CNV, and gene fusions were analyzed. Variants of unknown significance (VUS) were excluded from the analysis. Identified fusion genes were confirmed through cross&#8208;referencing with five publicly available fusion gene databases: FusionGDB2, TCGA Fusion Gene Database, Fusion Profiling Interactive Analysis, the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer, and the COSMIC Fusions database [<xref rid="cas70214-bib-0027" ref-type="bibr">27</xref>, <xref rid="cas70214-bib-0028" ref-type="bibr">28</xref>, <xref rid="cas70214-bib-0029" ref-type="bibr">29</xref>, <xref rid="cas70214-bib-0030" ref-type="bibr">30</xref>, <xref rid="cas70214-bib-0031" ref-type="bibr">31</xref>]. Additionally, relevant published literature was searched in PubMed to validate fusion events [<xref rid="cas70214-bib-0032" ref-type="bibr">32</xref>]. A fusion was defined as recurrent if it had been previously reported in at least one case of the same morphological STT subtype. If the fusion had not been previously reported in that same morphological soft tissue sarcoma (STS) subtype, it was defined as novel [<xref rid="cas70214-bib-0017" ref-type="bibr">17</xref>]. All fusion genes identified in the study were visualized using a Circos plot generated with the R package &#8220;circlize&#8221; (version 0.4.16 [RStudio, Boston, MA, USA]).</p></sec><sec id="cas70214-sec-0007"><label>2.5</label><title>Oncoplot of Reported Oncogenic Mutations</title><p>To visualize the overall landscape of identified genetic alterations, an Oncoplot was generated using the Julia package &#8220;CairoMakie&#8221; (version 0.10.4 [GitHub, San Francisco, CA, USA]). The visualization included single nucleotide variations (SNVs) and indels.</p></sec><sec id="cas70214-sec-0008"><label>2.6</label><title>Tumor Mutation Burden (<styled-content style="fixed-case" toggle="no">TMB</styled-content>)</title><p>TMB was assessed, and a high TMB (TMB&#8208;H) was defined as &#8805;&#8201;10&#8201;mut/Mb [<xref rid="cas70214-bib-0033" ref-type="bibr">33</xref>]. MSI scores were also evaluated and classified as either MSI&#8208;high (MSI&#8208;H) or microsatellite&#8208;stable (MSS).</p></sec><sec id="cas70214-sec-0009"><label>2.7</label><title>Evaluation of Germline Pathogenic Variants</title><p>Germline pathogenic variants (GPVs) were identified from genes assessed by the GenMine TOP panel [<xref rid="cas70214-bib-0034" ref-type="bibr">34</xref>, <xref rid="cas70214-bib-0035" ref-type="bibr">35</xref>]. The clinical significance of the detected germline variants was interpreted according to the classification guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) [<xref rid="cas70214-bib-0036" ref-type="bibr">36</xref>].</p></sec><sec id="cas70214-sec-0010"><label>2.8</label><title>Assessment of Study Outcomes</title><sec id="cas70214-sec-0011"><label>2.8.1</label><title>Statistical Analysis</title><p>We compared the detection rates of oncogenic gene alterations, including SNV, indels, CNV, and gene fusions, as well as druggable gene alterations, histology&#8208;specific fusion genes, and potentially therapeutically targetable kinase fusions between the F1CDx and GenMineTOP. Categorical variables were analyzed using Fisher's exact test. Overall survival (OS) was defined as the time from the date of CGP testing to the date of death from any cause or the last follow&#8208;up visit. Patients who were alive at the time of analysis were censored on the date of their most recent disease assessment. We evaluated the association between OS and the type of CGP panel used, as well as the receipt of genotype&#8208;matched therapy in patients who underwent CGP testing without a history of chemotherapy or during first or second&#8208;line chemotherapy. Survival curves were generated using the Kaplan&#8211;Meier method. Differences in survival were assessed using Cox proportional hazards regression analysis. A <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was considered statistically significant. All statistical analyses were conducted using BellCurve for Excel (Social Survey Research Information Co. Ltd., Tokyo, Japan).</p></sec></sec></sec><sec sec-type="results" id="cas70214-sec-0012"><label>3</label><title>Results</title><sec id="cas70214-sec-0013"><label>3.1</label><title>Patient Characteristics</title><p>A total of 1046 patients were included in this study, comprising 915 STS cases and 131 bone sarcoma cases (Table&#160;<xref rid="cas70214-supitem-0008" ref-type="supplementary-material">S5</xref>). F1CDx and GenMineTOP were used in 677 (64.7%) and 369 (35.3%) patients, respectively. Among the STS patients, uterine leiomyosarcoma (ULMS) was the most common subtype, diagnosed in 142 patients, followed by dedifferentiated liposarcoma (DDLS) in 118 patients and leiomyosarcoma (LMS) in 103 patients (Table&#160;<xref rid="cas70214-supitem-0009" ref-type="supplementary-material">S6</xref>). Osteosarcoma was the most commonly diagnosed bone sarcoma, accounting for 77 patients, followed by chondrosarcoma in 18 patients. TRS accounted for 160 patients, while 886 patients had genomically complex or other sarcomas. The median follow&#8208;up duration was 131&#8201;days (range: 6&#8211;407&#8201;days).</p></sec><sec id="cas70214-sec-0014"><label>3.2</label><title>Re&#8208;Classification</title><p>Based on the detection of highly histology&#8208;specific fusion genes from sequencing results, 16 (1.5%) patients were reclassified (Table&#160;<xref rid="cas70214-tbl-0001" ref-type="table">1</xref>). Reclassification occurred in seven patients (1.0%) in the F1CDx group and nine patients (2.4%) in the GenMineTOP group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.11). Two patients initially diagnosed with fibrosarcoma were reclassified as dermatofibrosarcoma protuberans (DFSP) based on the presence of the <italic toggle="yes">COL1A1&#8208;PDGFB</italic> fusion. Cases initially diagnosed as small round cell sarcoma and desmoplastic small round cell tumor were reclassified as <italic toggle="yes">CIC</italic>&#8208;rearranged sarcoma (CIC) and extraskeletal myxoid chondrosarcoma based on the detection of the <italic toggle="yes">CIC::DUX4</italic> and <italic toggle="yes">NR4A3::EWSR1</italic> fusions, respectively. Four patients originally diagnosed as sarcoma NOS were reclassified as <italic toggle="yes">NTRK</italic>&#8208;rearranged spindle cell neoplasm (NTRK), <italic toggle="yes">CIC</italic>&#8208;rearranged sarcoma, sarcoma with <italic toggle="yes">BCOR</italic> genetic alterations (BCOR), and SYNS, based on the fusion genes <italic toggle="yes">EML4::NTRK3</italic>, <italic toggle="yes">CIC::DUX4</italic>, <italic toggle="yes">BCOR::CCNB3</italic>, and <italic toggle="yes">EWSR1::SSX1</italic>, respectively.</p><table-wrap position="float" id="cas70214-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Reclassification based on genomic data.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Initial diagnosis</th><th align="center" valign="bottom" rowspan="1" colspan="1">Reclassified diagnosis</th><th align="center" valign="bottom" rowspan="1" colspan="1">Genomic specificity</th><th align="center" valign="bottom" rowspan="1" colspan="1">Patients, number</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Desmoplastic small round cell tumor</td><td align="center" valign="top" rowspan="1" colspan="1">Extraskeletal myxoid chondrosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">NR4A3::EWSR1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (F)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ewing sarcoma (soft tissue)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CIC</italic>&#8208;rearranged sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CIC::DUX4</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (F)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fibrosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">Dermatofibrosarcoma protuberans</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">COL1A1::PDGFB</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">2 (G)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sarcoma, NOS</td><td align="center" valign="top" rowspan="1" colspan="1">Sarcoma with <italic toggle="yes">BCOR</italic> genetic alterations</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">BCOR::CCNB3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (G)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CIC</italic>&#8208;rearranged sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CIC::DUX4</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">4 (G;2, F2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Epithelioid hemangioendothelioma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">WWTR1::CAMTA1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (G)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Extraskeletal myxoid chondrosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EWSR1::NR4A3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (F)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">NTRK</italic>&#8208;rearranged spindle cell neoplasm</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EML4::NTRK3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (G)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">Synovial sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ETV6::NTRK3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (G)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">LMNA::NTRK1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (F)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EWSR1::SSX1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (F)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spindle cell/sclerosing rhabdomyosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">Alveolar rhabdomyosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">PAX3::FOXO1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (G)</td></tr></tbody></table><table-wrap-foot id="cas70214-ntgp-0002"><fn id="cas70214-note-0002"><p>Abbreviations: F, FoundationOne CDx cancer genome profiling; G, GenMine TOP Cancer Genome Profiling System.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cas70214-sec-0015"><label>3.3</label><title>Profiling of Genomic Alterations</title><p>Oncogenic gene alterations (SNVs/indels, CNV, and fusions) were detected in 650 (96.0%) patients using F1CDx and 275 (74.5%) patients using GenMineTOP (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Table&#160;<xref rid="cas70214-tbl-0002" ref-type="table">2</xref>). SNVs/indels were observed in 493 (72.8%) patients in the F1CDx group and 203 (55.0%) patients in the GenMineTOP group (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Table&#160;<xref rid="cas70214-tbl-0002" ref-type="table">2</xref>). These alterations are shown in the Oncoplot (Figure&#160;<xref rid="cas70214-fig-0001" ref-type="fig">1</xref>). The most frequently mutated gene was <italic toggle="yes">TP53</italic>, followed by <italic toggle="yes">KIT</italic>, <italic toggle="yes">RB1</italic>, <italic toggle="yes">TERT</italic>, <italic toggle="yes">NF1</italic>, and <italic toggle="yes">PIK3CA</italic> (Table&#160;<xref rid="cas70214-supitem-0010" ref-type="supplementary-material">S7</xref>). The most common SNVs/indels in the F1CDx group were <italic toggle="yes">TP53</italic> (35.2%), <italic toggle="yes">KIT</italic> (14.6%), and <italic toggle="yes">RB1</italic> (7.5%). In the GenMineTOP group, the most common were <italic toggle="yes">TP53</italic> (24.7%), <italic toggle="yes">TER</italic>T (6.8%), and <italic toggle="yes">RB1</italic> (5.7%) (Figures&#160;<xref rid="cas70214-supitem-0001" ref-type="supplementary-material">S1A&#8211;C</xref>). CNVs were observed in 488 (72.1%) and 105 (28.5%) patients with F1CDx and GenMineTOP, respectively (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Table&#160;<xref rid="cas70214-tbl-0002" ref-type="table">2</xref>). In the GenMineTOP, the most frequently amplified genes were cyclin&#8208;dependent kinase 4 (<italic toggle="yes">CDK4</italic>) (14.4%), <italic toggle="yes">MDM2</italic> (13.3%), and <italic toggle="yes">CCND3</italic> (3.5%). In the F1CDx group, cyclin&#8208;dependent kinase inhibitor 2A (<italic toggle="yes">CDKN2A</italic>) (23.8%), <italic toggle="yes">CDKN2B</italic>, and <italic toggle="yes">MDM2</italic> (16.2%) were the most commonly altered (Figures&#160;<xref rid="cas70214-supitem-0001" ref-type="supplementary-material">S1D&#8211;F</xref>). The highest evidence&#8208;level classifications of druggable gene alterations, as defined in the C&#8208;CAT system, are shown in Table&#160;<xref rid="cas70214-tbl-0002" ref-type="table">2</xref>. Druggable alterations were identified in 418 patients (40.0%). GenMineTOP identified a significantly higher proportion of druggable gene alterations compared to F1CDx (47.7% vs. 35.7%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p><table-wrap position="float" id="cas70214-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Oncogenic and druggable gene alteration.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1">F1CDx (<italic toggle="yes">n</italic>&#8201;=&#8201;677)</th><th align="center" valign="bottom" rowspan="1" colspan="1">GenMineTOP (<italic toggle="yes">n</italic>&#8201;=&#8201;369)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Oncogenic gene alteration</td><td align="center" valign="top" rowspan="1" colspan="1">650 (96.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">275 (74.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Single nucleotide variants</td><td align="center" valign="top" rowspan="1" colspan="1">493 (72.8%)</td><td align="center" valign="top" rowspan="1" colspan="1">203 (55.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Copy&#8208;number variation</td><td align="center" valign="top" rowspan="1" colspan="1">488 (72.1%)</td><td align="center" valign="top" rowspan="1" colspan="1">105 (28.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Evidence&#8208;level classifications for druggable gene alterations</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">A</td><td align="center" valign="top" rowspan="1" colspan="1">96 (14.2%)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (3.5%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">B</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.3%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">C</td><td align="center" valign="top" rowspan="1" colspan="1">139 (20.5%)</td><td align="center" valign="top" rowspan="1" colspan="1">169 (45.8%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">D</td><td align="center" valign="top" rowspan="1" colspan="1">7 (1.0%)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.3%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1">242 (35.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">176 (47.7%)</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot id="cas70214-ntgp-0003"><fn id="cas70214-note-0003"><p>Abbreviations: F1CDx, FoundationOne CDx cancer genome profiling; GenMineTOP; GenMine TOP Cancer Genome Profiling System.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="cas70214-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Oncogenic gene alteration by subtype. Oncoplot of oncogenic genomic alterations (SNV/Indels) identified in the study population. Oncogenic genomic alterations in specific genes detected at a frequency &gt;&#8201;0.3% and tumor subtypes at a frequency &gt;&#8201;10 cases are shown. Tumor subtypes are represented in colored text below Oncoplot. The histogram on top of the mutation Oncoplot represents the number of mutations per patient.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CAS-117-156-g002.jpg"/></fig></sec><sec id="cas70214-sec-0016"><label>3.4</label><title>Gene Fusions</title><p>A total of 127 fusion genes were identified in 125 patients (12.0%), with two patients harboring two distinct fusion genes. Fusion genes were detected in 50 patients using F1CDx (7.4%) and in 75 patients (20.3%) using the RNA panel of GenMineTOP (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). These results are visualized in the Circos plot (Figure&#160;<xref rid="cas70214-fig-0002" ref-type="fig">2A,B</xref>). Among the patients with TRS, histology&#8208;specific fusion genes were detected in 94 cases. These included <italic toggle="yes">SYT::SSX</italic> in SYNS, <italic toggle="yes">EWSR1::FLI1</italic> in ES, <italic toggle="yes">PAX3::FOXO1</italic> in alveolar rhabdomyosarcoma, <italic toggle="yes">BCOR::CCNB3</italic> in sarcoma with <italic toggle="yes">BCOR</italic> genetic alterations, and <italic toggle="yes">ASPSCR1::TFE3</italic> in alveolar soft tissue sarcoma. Histology&#8208;specific fusion genes were identified in 32 of 80 TRS cases (40.0%) using F1CDx and in 62 of 80 TRS cases (77.5%) using GenMineTOP (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Table&#160;<xref rid="cas70214-tbl-0003" ref-type="table">3</xref>). Potentially therapeutically targetable kinase fusions were found in 21 patients (2.0%). These included six cases each of <italic toggle="yes">NTRK</italic> and <italic toggle="yes">FGFR</italic> fusions, two cases each of <italic toggle="yes">BRAF, RAF1</italic>, and <italic toggle="yes">ALK</italic> fusions, and one case each of <italic toggle="yes">RET</italic>, <italic toggle="yes">ROS1</italic>, and <italic toggle="yes">EGFR</italic> fusions. These fusions were detected in eight patients (1.2%) using F1CDx and in 13 patients (3.5%) using GenMineTOP (<italic toggle="yes">p</italic>&#8201;=&#8201;0.019). Additionally, 25 novel fusion events were identified in 24 patients (Table&#160;<xref rid="cas70214-tbl-0004" ref-type="table">4</xref>), including 16 patients (2.4%) using F1CDx and nine patients (2.4%) using GenMineTOP.</p><fig position="float" fig-type="FIGURE" id="cas70214-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Circos plot of identified fusion genes. The identified fusion genes were visually represented in the Circos plot. (A) FoundationOne CDx cancer genome profiling. (B) GenMine TOP Cancer Genome Profiling System.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CAS-117-156-g001.jpg"/></fig><table-wrap position="float" id="cas70214-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>The difference of the detection of common recurrent fusion.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Histology of translocation&#8208;related sarcomas</th><th align="center" rowspan="2" valign="bottom" colspan="1">Common recurrent fusion</th><th align="center" colspan="2" valign="bottom" rowspan="1">Patients, number</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">GenMineTOP</th><th align="center" valign="bottom" rowspan="1" colspan="1">F1CDx</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Alveolar rhabdomyosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">PAX3::FOXO1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">8 (9)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alveolar soft part sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ASPSCR1::TFE3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">6 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Clear cell sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EWSR1::ATF1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">5 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CIC</italic>&#8208;rearranged sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CIC::DUX4</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dermatofibrosarcoma protuberans</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">COL1A1::PDGFB</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Desmoplastic small round cell tumor</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EWSR1::WT1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Epithelioid hemangioendothelioma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">WWTR1::CAMTA1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (7)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Extraskeletal myxoid chondrosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EWSR1::NR4A3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (4)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">NR4A3::EWSR1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">Ewing sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EWSR1::FLI1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">9 (13)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (16)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EWSR1::ERG</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ERG::EWSR1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sarcoma with <italic toggle="yes">BCOR</italic> genetic alterations</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">BCOR::CCNB3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Infantile fibrosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0 (1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Myxoid/round cell liposarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">FUS::DDIT3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (4)</td></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">
<italic toggle="yes">NTRK</italic>&#8208;rearranged spindle cell neoplasm</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EML4::NTRK3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ETV6::NTRK3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">LMNA::NTRK1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Solitary fibrous tumor</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">NAB2::STAT6</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">7 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (12)</td></tr><tr><td align="left" rowspan="2" valign="top" colspan="1">Synovial sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SS18::SSX1, 2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">15 (17)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (15)</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EWSR1::SSX1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mesenchymal chondrosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">HEY1::NCOA2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (2)</td></tr></tbody></table><table-wrap-foot id="cas70214-ntgp-0004"><fn id="cas70214-note-0004"><p>Abbreviations: F1CDx, FoundationOne CDx cancer genome profiling; GenMineTOP, GenMine TOP Cancer Genome Profiling System.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="cas70214-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Novel Gene Fusions in sarcoma subtypes.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Rearrangement&#8208;1&#8208;MARKER</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gender</th><th align="center" valign="bottom" rowspan="1" colspan="1">Age</th><th align="center" valign="bottom" rowspan="1" colspan="1">Diagnosis</th><th align="center" valign="bottom" rowspan="1" colspan="1">Panel</th><th align="center" valign="bottom" rowspan="1" colspan="1">Rearrangement&#8208;1&#8208;METHOD</th><th align="center" valign="bottom" rowspan="1" colspan="1">Rearrangement&#8208;1&#8208;TRANSCRIPT_ID</th><th align="center" valign="bottom" rowspan="1" colspan="1">Previously reported malignancy</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">KMT2A::ELL</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">Sarcoma, NOS</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">ENST00000389506&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006532">NM_006532</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">Acute myeloid leukemia, acute lymphoblastic leukemia/lymphoblastic lymphoma, Acute monoblastic leukemia</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">HMGA2::MSRB3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">41</td><td align="center" valign="top" rowspan="1" colspan="1">Undifferentiated pleomorphic sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_003483">NM_003483</ext-link>&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_198080">NM_198080</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">Bladder urothelial carcinoma, head and neck squamous cell carcinomas, thyroid cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">GOLGB1::RAF1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">66</td><td align="center" valign="top" rowspan="1" colspan="1">Clear cell sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_004487">NM_004487</ext-link>&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_002880">NM_002880</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">FGFR1::RBFOX2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">Dedifferentiated liposarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_023110">NM_023110</ext-link>&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001349998">NM_001349998</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">FGFR1::DDHD2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">80</td><td align="center" valign="top" rowspan="1" colspan="1">Dedifferentiated liposarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_001174067">NM_001174067</ext-link>&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_015214">NM_015214</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">RBPMS::NTRK2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">Malignant peripheral nerve sheath tumor</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006867">NM_006867</ext-link>&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006180">NM_006180</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">Astrocytoma, glioblastoma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">FGFR1::HOOK3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">Uterine leiomyosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_023110">NM_023110</ext-link>&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_032410">NM_032410</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">HTT::NTRK2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">Chondrosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_002111">NM_002111</ext-link>&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_006180">NM_006180</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">FGFR2::ATE1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">Osteosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">GenMineTOP</td><td align="center" valign="top" rowspan="1" colspan="1">RNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_023029">NM_023029</ext-link>&#8208;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="NM_007041">NM_007041</ext-link></td><td align="center" valign="top" rowspan="1" colspan="1">Bladder urothelial carcinoma, breast invasive carcinoma, lung adenocarcinoma, uterine corpus endometrial carcinoma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">KTN1::RAF1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">Undifferentiated pleomorphic sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CDK4::NTRK2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">Leiomyosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CCDC171::CCND3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">Gastrointestinal Stromal Tumor</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">HAUS8::NOTCH3</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">55</td><td align="center" valign="top" rowspan="1" colspan="1">Myxofibrosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">MET::LUZP6</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">65</td><td align="center" valign="top" rowspan="1" colspan="1">Leiomyosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EGFR::VOPP1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">Undifferentiated pleomorphic sarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">KIAA1244::ROS1</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">Dedifferentiated liposarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ROS1::HBS1L</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">Dedifferentiated liposarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ENPP1::MYB</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">Dedifferentiated liposarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CDK4::ZCCHC17</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">65</td><td align="center" valign="top" rowspan="1" colspan="1">Sarcoma, NOS</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">NOTCH1::SEC16A</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="center" valign="top" rowspan="1" colspan="1">Angiosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">Lung squamous cell carcinoma, head and neck squamous cell carcinomas, thyroid cancer, breast cancer</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CCND2::CTNND2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">66</td><td align="center" valign="top" rowspan="1" colspan="1">Dedifferentiated liposarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">BRAF::DLG2</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">Malignant peripheral nerve sheath tumor</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">JAK1::FNBP1L</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Man</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">Malignant peripheral nerve sheath tumor</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">MET::KIAA1549</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">Malignant peripheral nerve sheath tumor</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ALK::PPP2R3A</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Woman</td><td align="center" valign="top" rowspan="1" colspan="1">55</td><td align="center" valign="top" rowspan="1" colspan="1">Uterine leiomyosarcoma</td><td align="center" valign="top" rowspan="1" colspan="1">F1CDx</td><td align="center" valign="top" rowspan="1" colspan="1">DNA&#8208;seq</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot id="cas70214-ntgp-0005"><fn id="cas70214-note-0005"><p>Abbreviations: F1CDx, FoundationOne CDx cancer genome profiling; GenMineTOP, GenMine TOP Cancer Genome Profiling System.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cas70214-sec-0017"><label>3.5</label><title>TMB</title><p>TMB data were available for all patients except two. The median TMB was 1.6 mutations per megabase (range: 0&#8211;152). TMB&#8208;H was observed in 22 patients (2.1%). These included five patients with ULMS (3.5%), four with ANGS (5.6%), and two each with LMS (1.9%), UPS (3.2%), OS (2.6%), and SARCNOS (2.7%). TMB&#8208;H was identified in 19 patients (2.8%) using F1CDx and in three patients (0.8%) using GenMineTOP (<italic toggle="yes">p</italic>&#8201;=&#8201;0.04). Microsatellite instability status was observed in six cases, all of whom underwent F1CDx testing. All six cases were also classified as TMB&#8208;high.</p></sec><sec id="cas70214-sec-0018"><label>3.6</label><title>Targetable Genomic Alterations in <styled-content style="fixed-case" toggle="no">STS</styled-content> and the Clinical Impact of Genotype&#8208;Matched Therapy</title><p>In non&#8208;Gastrointestinal Stromal Tumor (GIST) sarcomas, clinical information regarding the recommendation for genotype&#8208;matched therapy was available for 695 patients (206 with therapy recommendations, 489 without). Genotype&#8208;matched therapy was administered to 22 patients (3.2%), including 12 of 464 patients (2.6%) in the F1CDx group and 10 of 231 patients (4.3%) in the GenMineTOP group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.25) (Table&#160;<xref rid="cas70214-tbl-0002" ref-type="table">2</xref>). Therapies administered included 13 approved drugs, such as targeted small&#8208;molecule inhibitors (<italic toggle="yes">n</italic>&#8201;=&#8201;8; e.g., pazopanib, Larotrectinib) and immune checkpoint inhibitors (<italic toggle="yes">n</italic>&#8201;=&#8201;5; e.g., pembrolizumab). Additionally, nine off&#8208;label drugs were used, comprising two targeted small&#8208;molecule inhibitors and seven clinical trials. Molecular targeted therapy was administered more frequently in the GenMineTOP group (10 of 231 patients, 4.3%) than in the F1CDx group (7 of 464 patients, 1.5%) (<italic toggle="yes">p</italic>&#8201;=&#8201;0.03).</p></sec><sec id="cas70214-sec-0019"><label>3.7</label><title>
<styled-content style="fixed-case" toggle="no">GPVs</styled-content>
</title><p>GPVs were detected in 21 patients (5.7%) using the tumor&#8211;normal matched GenMineTOP panel (Table&#160;<xref rid="cas70214-supitem-0011" ref-type="supplementary-material">S8</xref>). The affected genes included <italic toggle="yes">TP53</italic> (two cases of DDLS and one case each of OS, LMS, and UPS); <italic toggle="yes">NF1</italic> (three cases of MPNST and two cases of GIST); <italic toggle="yes">BRCA2</italic> (one case each of ULMS, WDLS, and SARCNOS); and <italic toggle="yes">PMS2</italic> (one case each of OS and SARCNOS). Allele frequencies ranged from 21.9% to 55.2%. Fifteen patients had a family history of cancer. According to the ACMG/AMP classification guidelines, 20 variants were classified as pathogenic and one as likely pathogenic.</p></sec><sec id="cas70214-sec-0020"><label>3.8</label><title>Association Between <styled-content style="fixed-case" toggle="no">OS</styled-content>, <styled-content style="fixed-case" toggle="no">CGP</styled-content> Test Type, and Receipt of Genotype&#8208;Matched Therapy</title><p>The 1&#8208;year OS rates of patients tested with F1CDx and GenMineTOP were 62.6% and 63.9%, respectively (<italic toggle="yes">p</italic>&#8201;=&#8201;0.80) (Figure&#160;<xref rid="cas70214-supitem-0002" ref-type="supplementary-material">S2</xref>). Among all patients, the 6&#8208;month OS rates were 100% for those who received genotype&#8208;matched therapy, 81.0% for patients with druggable alterations who did not receive genomically matched therapy, and 81.5% for patients without druggable alterations (<italic toggle="yes">p</italic>&#8201;=&#8201;0.38) (Figure&#160;<xref rid="cas70214-supitem-0003" ref-type="supplementary-material">S3A</xref>). In the F1CDx cohort, the corresponding 6&#8208;month OS rates were 100%, 82.6%, and 81.5%, respectively (<italic toggle="yes">p</italic>&#8201;=&#8201;0.98) (Figure&#160;<xref rid="cas70214-supitem-0003" ref-type="supplementary-material">S3B</xref>). In the GenMineTOP cohort, the 6&#8208;month OS rates were 100% for patients who received genotype&#8208;matched therapy, 72.8% for those with druggable alterations who did not receive genomically matched therapy, and 83.6% for patients without druggable alterations (<italic toggle="yes">p</italic>&#8201;=&#8201;0.076) (Figure&#160;<xref rid="cas70214-supitem-0003" ref-type="supplementary-material">S3C</xref>).</p></sec></sec><sec sec-type="discussion" id="cas70214-sec-0021"><label>4</label><title>Discussion</title><p>This study suggests that a dual DNA&#8211;RNA panel covered by public health insurance may improve diagnostic accuracy and therapeutic decision&#8208;making for sarcoma in clinical practice. Compared to conventional DNA&#8208;only panels like F1CDx, GenMineTOP demonstrated superior performance in detecting fusion genes and therapeutically targetable kinase fusions, particularly in TRS. Moreover, its integrated tumor&#8211;normal matched analysis identified GPVs, highlighting its potential for personalized surveillance and preventive strategies for patients and their at&#8208;risk relatives.</p><p>Boddu et&#160;al. reported that <italic toggle="yes">TP53</italic> (36.8%), <italic toggle="yes">CDKN2A/B</italic> (20.2%), <italic toggle="yes">CDK4/MDM2</italic> (19.3%), <italic toggle="yes">ATRX</italic> (13.2%), and <italic toggle="yes">RB1</italic> (13.2%) were among the most frequent oncogenic mutations detected using CGP in patients with advanced or metastatic sarcoma [<xref rid="cas70214-bib-0019" ref-type="bibr">19</xref>]. Consistent with previous findings, this study found <italic toggle="yes">TP53</italic>, <italic toggle="yes">KIT</italic>, and <italic toggle="yes">RB1</italic> to be the most frequently altered genes in the SNV category. The most frequently mutated genes were nearly identical between the F1CDx and GenMineTOP cohorts. While F1CDx demonstrated a higher overall detection rate of oncogenic gene alterations, GenMineTOP identified a significantly greater proportion of druggable gene alterations, suggesting its clinical utility in identifying actionable mutations.</p><p>A key advantage of GenMineTOP over DNA&#8208;only panels lies in its ability to accurately detect gene fusions through RNA&#8208;based analysis. DNA fusion panels may fail to identify functional fusions due to factors such as transcriptional silencing, epigenetic modifications, structural rearrangements, or post&#8208;transcriptional regulation [<xref rid="cas70214-bib-0017" ref-type="bibr">17</xref>]. GenMineTOP addresses these limitations by using an RNA&#8208;based approach, resulting in a significantly higher detection rate of fusion genes than F1CDx (20.3% vs. 7.4%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). The histopathological diagnosis of sarcomas remains challenging, and CGP reportedly contributes to diagnostic reclassification in approximately 4%&#8211;10% of cases&#160;[<xref rid="cas70214-bib-0019" ref-type="bibr">19</xref>, <xref rid="cas70214-bib-0021" ref-type="bibr">21</xref>]. In this study, GenMineTOP enabled reclassification in 2.4% of patients, compared with 1.0% using F1CDx. For example, the identification of the <italic toggle="yes">COL1A1::PDGFB</italic> fusion by GenMineTOP led to the reclassification of two cases initially diagnosed as fibrosarcoma to the fibrosarcomatous variant of dermatofibrosarcoma protuberans (FS&#8208;DFSP). This is a clinically meaningful distinction, as FS&#8208;DFSP is classified as an intermediate tumor under the WHO classification and is typically treated with imatinib as first&#8208;line therapy per NCCN guidelines, whereas fibrosarcoma is considered malignant and generally treated with doxorubicin [<xref rid="cas70214-bib-0037" ref-type="bibr">37</xref>, <xref rid="cas70214-bib-0038" ref-type="bibr">38</xref>]. Therefore, the accurate classification of these two entities, given their differing prognoses and therapeutic approaches, is of significant clinical importance. In this study, sarcoma NOS cases were reclassified as <italic toggle="yes">NTRK</italic>&#8208;rearranged spindle cell neoplasm, <italic toggle="yes">CIC</italic>&#8208;rearranged sarcoma, sarcoma with <italic toggle="yes">BCOR</italic> genetic alterations, or SYNS based on the detection of histology&#8208;specific fusion genes such as <italic toggle="yes">EML4::NTRK3</italic>, <italic toggle="yes">CIC::DUX4</italic>, <italic toggle="yes">BCOR::CCNB3</italic>, and <italic toggle="yes">EWSR1::SSX1</italic>. The identification of histology&#8208;specific fusion genes is particularly crucial in TRS, where molecular characterization informs diagnosis and therapeutic strategy [<xref rid="cas70214-bib-0039" ref-type="bibr">39</xref>, <xref rid="cas70214-bib-0040" ref-type="bibr">40</xref>]. However, most DNA&#8208;only panels detect a limited spectrum of fusion genes. For example, histology&#8208;specific fusion genes were detected in only 40.0% of patients with TRS using F1CDx. In contrast, GenMineTOP identified 455 fusion genes, encompassing the majority of histology&#8208;specific fusions reported in bone and soft tissue tumors, and enabled their detection in 77.5% of patients with TRS.</p><p>In sarcoma, the proportion of patients with potentially druggable alterations and those who actually receive genotype&#8208;matched therapy in real&#8208;world settings reportedly range from 47% to 61%, and from 7.3% to 8.8%, respectively [<xref rid="cas70214-bib-0019" ref-type="bibr">19</xref>, <xref rid="cas70214-bib-0020" ref-type="bibr">20</xref>, <xref rid="cas70214-bib-0021" ref-type="bibr">21</xref>]. In our cohort, 40.0% of patients harbored at least one druggable alteration. Genotype&#8208;matched therapies, including targeted small&#8208;molecule inhibitors, immune checkpoint inhibitors, and clinical trials, were administered in 3.2% of patients: 2.6% in the F1CDx group and 4.3% in the GenMineTOP group. Although this overall rate is lower than those reported in earlier studies, this may reflect limitations such as the unavailability of approved therapies or ongoing clinical trials, restricted access to specialized treatment centers, or disease progression prior to therapy initiation [<xref rid="cas70214-bib-0019" ref-type="bibr">19</xref>, <xref rid="cas70214-bib-0020" ref-type="bibr">20</xref>, <xref rid="cas70214-bib-0041" ref-type="bibr">41</xref>]. Targeted therapies and immunotherapies represent promising treatment options for sarcomas identified through CGP, which have the potential to improve outcomes. Tyrosine kinase inhibitors (TKIs), for instance, have demonstrated strong efficacy in tumors harboring oncogenic fusion genes involving kinase activity&#160;[<xref rid="cas70214-bib-0042" ref-type="bibr">42</xref>]. These include ALK inhibitors such as crizotinib and alectinib for <italic toggle="yes">ALK</italic> fusion&#8208;positive sarcomas, and TRK inhibitors such as larotrectinib and entrectinib for <italic toggle="yes">NTRK</italic> fusion&#8208;positive sarcomas [<xref rid="cas70214-bib-0043" ref-type="bibr">43</xref>]. In our study, potentially actionable kinase fusions, including <italic toggle="yes">ALK</italic>, <italic toggle="yes">PDGFRA</italic>, <italic toggle="yes">NTRK1,2</italic>, and <italic toggle="yes">ROS1</italic>, were identified more frequently by GenMineTOP (3.5%) than by F1CDx (1.2%). Moreover, molecular targeted therapy, including the use of TRK inhibitors, was more frequently administered in patients analyzed by GenMineTOP than by F1CDx for non&#8208;GIST sarcomas (4.3% vs. 2.6%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.03). These findings suggest that the combined DNA and RNA profiling approach used in GenMineTOP enhances the detection of fusion genes, which may expand therapeutic opportunities in sarcoma management.</p><p>Tumor sequencing data contain a mixture of somatic mutations and variants of germline origin. Matched tumor&#8211;normal testing provides a more accurate distinction between these two categories and is an efficient approach for both somatic and germline analysis [<xref rid="cas70214-bib-0044" ref-type="bibr">44</xref>]. This approach enables timely personalized cancer management, facilitates appropriate surveillance and preventative interventions for patients and at&#8208;risk relatives, and supports the selection of targeted molecular therapies. Kikuchi et&#160;al. identified PGPVs in 15.2% of patients using F1CDx, a tumor&#8208;only panel, whereas GPVs were detected in 16.7% of patients using the NCC Onco&#8208;panel, a paired tumor&#8211;normal matched test [<xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>]. The hereditary contribution to sarcoma has long been recognized, and several cancer predisposition genes have been implicated, including <italic toggle="yes">TP53</italic>, <italic toggle="yes">BRCA1/2</italic>, <italic toggle="yes">RB1</italic>, and <italic toggle="yes">NF1</italic> [<xref rid="cas70214-bib-0013" ref-type="bibr">13</xref>]. However, reports on the detection rates of germline pathogenic variants using CGP in real&#8208;world sarcoma cases remain limited. This is largely due to the widespread use of tumor&#8208;only CGP panels, which cannot reliably distinguish germline from somatic mutations. In contrast, GenMineTOP incorporates tumor&#8211;normal matching design and identified GPVs in 5.7% of patients in our study. Most of these mutations occurred in genes associated with homologous recombination repair or known hereditary cancer syndromes, including <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">TP53</italic>, and <italic toggle="yes">NF1</italic>. It is likely that some of these patients carried underlying hereditary cancer syndromes such as neurofibromatosis type 1 (NF1) or Li&#8208;Fraumeni syndrome [<xref rid="cas70214-bib-0045" ref-type="bibr">45</xref>]. An additional advantage of detecting germline mutations is their relevance to targeted therapies. Germline defects in homologous recombination repair genes, such as <italic toggle="yes">BRCA1</italic> and <italic toggle="yes">BRCA2</italic>, are predictive biomarkers for response to PARP inhibitors [<xref rid="cas70214-bib-0044" ref-type="bibr">44</xref>]. Therefore, integrating germline testing into clinical cancer management is increasingly necessary to guide both therapeutic strategies and genetic counseling.</p><p>The effectiveness of genotype&#8208;matched therapies guided by CGP in improving survival outcomes across cancer types remains controversial [<xref rid="cas70214-bib-0046" ref-type="bibr">46</xref>, <xref rid="cas70214-bib-0047" ref-type="bibr">47</xref>]. While several studies showed promising results, others report limited clinical benefits. For example, Ida et&#160;al. reported that 12.2% of patients received genotype&#8208;matched therapy following CGP, and those who had significantly longer overall survival compared to those who did not (<italic toggle="yes">p</italic>&#8201;=&#8201;0.032) [<xref rid="cas70214-bib-0046" ref-type="bibr">46</xref>]. However, the type of CGP panel used was not significantly associated with OS, suggesting that the specific panel employed may not be the decisive factor influencing prognosis.</p><p>In our study, among patients tested with GenMineTOP, those who received genotype&#8208;matched therapy demonstrated a trend toward improved 6&#8208;month overall survival compared to patients with druggable alterations who did not receive matched therapy and patients without druggable alterations. These findings suggest a potential clinical benefit of genotype&#8208;matched therapy. Future studies with larger patient cohorts and longer follow&#8208;up durations are needed to better assess the survival benefits of genomically matched therapies in sarcoma.</p><p>This study had some limitations. First, the C&#8208;CAT database lacks detailed clinical information on surgical procedures, radiation therapy, referral for genetic testing and/or genetic counseling, and treatment response, making it difficult to correlate genomic alterations with clinical outcomes in a comprehensive manner. Second, due to the retrospective nature, there is a risk of selection bias in determining which patients underwent CGP testing. To better assess the utility of CGP panels in sarcoma care, a prospective study including all patients over a defined period would provide more robust evidence. Third, the clinical response to genotype&#8208;matched therapies could not be evaluated due to insufficient data on treatment efficacy for the drugs recommended. Fourth, GeneMineTOP was introduced relatively recently, resulting in a short follow&#8208;up period. This limited observation window restricted our ability to evaluate its long&#8208;term clinical impact and effectiveness.</p><p>In conclusion, GenMineTOP identified more druggable gene alterations than F1CDx in patients with sarcoma. The superiority of GenMineTOP over other DNA panels is its ability to accurately identify histology&#8208;specific fusion genes in TRS and potentially therapeutically targetable kinase fusions using an RNA panel. Additionally, its use of tumor&#8211;normal matched testing enabled the detection of germline pathogenic variants. Results suggest that GenMineTOP may be a valuable tool for guiding precision oncology in sarcoma. Its potential to improve prognosis through genomically matched therapy should be further validated in a large&#8208;scale, prospective study.</p></sec><sec id="cas70214-sec-0028"><title>Author Contributions</title><p>
<bold>Eiji Nakata:</bold> conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, writing &#8211; original draft, writing &#8211; review and editing. <bold>Kiichiro Ninomiya:</bold> conceptualization, investigation, writing &#8211; original draft. <bold>Tatsunori Osone:</bold> investigation, writing &#8211; review and editing. <bold>Daisuke Ennishi:</bold> conceptualization, investigation, writing &#8211; original draft. <bold>Shuta Tomida:</bold> conceptualization, investigation, writing &#8211; original draft. <bold>Tomohiro Fujiwara:</bold> conceptualization, investigation, writing &#8211; original draft. <bold>Toshiyuki Kunisada:</bold> conceptualization, investigation, writing &#8211; original draft. <bold>Mashu Futagawa:</bold> conceptualization, investigation, writing &#8211; original draft. <bold>Akira Hirasawa:</bold> conceptualization, investigation, writing &#8211; original draft. <bold>Shinichi Toyooka:</bold> conceptualization, project administration, writing &#8211; original draft. <bold>Toshifumi Ozaki:</bold> conceptualization, investigation, writing &#8211; original draft.</p></sec><sec id="cas70214-sec-0026"><title>Ethics Statement</title><p>Approval of the research protocol by an Institutional Reviewer Board. This study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of Okayama University Hospital approved this study (approval number K2111&#8208;047).</p></sec><sec sec-type="conclusions" id="cas70214-sec-0027"><title>Consent</title><p>All informed consent was obtained from the patients.</p></sec><sec sec-type="COI-statement" id="cas70214-sec-0025"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cas70214-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S1:</bold> The types and number of oncogenic gene alteration. (A) In total, the most frequently mutated genes were <italic toggle="yes">TP53</italic>, following <italic toggle="yes">KIT</italic>, and <italic toggle="yes">RB1</italic> in SNVs/Indels. (B) The most common SNV/Indels being <italic toggle="yes">TP53</italic>, <italic toggle="yes">KIT</italic>, and <italic toggle="yes">RB1</italic> in FoundationOne CDx cancer genome profiling. (C) The most common SNV/Indels being <italic toggle="yes">TP53</italic>, <italic toggle="yes">TER</italic>T, and <italic toggle="yes">RB1</italic> in GenMine TOP Cancer Genome Profiling System.</p><p>(D) In total, the most common CNV being cyclin&#8208;dependent kinase inhibitor 2A, <italic toggle="yes">MDM2</italic>, and <italic toggle="yes">CDK4</italic>. (E) The most common CNV being cyclin&#8208;dependent kinase inhibitor 2A, cyclin&#8208;dependent kinase inhibitor 2B, and <italic toggle="yes">MDM2</italic> in FoundationOne CDx cancer genome profiling. (F) The most common CNV being <italic toggle="yes">CDK4</italic> and <italic toggle="yes">MDM2</italic> in GenMine TOP Cancer Genome Profiling System.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s008.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S2:</bold> Association between overall survival and kind of comprehensive cancer genomic profiling tests. The kind of panel had no association with overall survival. F1CDx; FoundationOne CDx cancer genome profiling. GenMineTOP; GenMine TOP Cancer Genome Profiling System.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s010.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S3:</bold> Association between overall survival and the receivement of genomically matched therapy. (A) Overall survival of patients who received genotype&#8208;matched therapy, patients with druggable alteration not receiving genomically matched therapy, and patients without druggable alteration. (B) Overall survival of patients who received genotype&#8208;matched therapy, patients with druggable alteration not receiving genomically matched therapy, and patients without druggable alteration in FoundationOne CDx cancer genome profiling. (C) Overall survival of patients who received genotype&#8208;matched therapy, patients with druggable alteration not receiving genomically matched therapy, and patients without druggable alteration in GenMine TOP Cancer Genome Profiling System.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s004.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S1:</bold> Categorization of sarcoma types.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S2:</bold> Comprehensive cancer genomic profiling tests.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s001.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S3:</bold> Gene list tested in each comprehensive genomic profiling test.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s005.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0007" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S4:</bold> Evidence levels based on clinical practice guidance for next&#8208;generation sequencing in cancer diagnosis and treatment (Edition 2.0).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s009.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0008" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S5:</bold> Patient characteristics.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s007.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0009" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S6:</bold> Histology of the patients.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s006.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0010" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S7:</bold> Profiling of genomic alterations.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s003.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="cas70214-supitem-0011" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table&#160;S8:</bold> Germline findings.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CAS-117-156-s011.xlsx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="cas70214-sec-0022"><title>Acknowledgments</title><p>We thank Editage for English language processing and editing.</p></ack><sec sec-type="data-availability" id="cas70214-sec-0024"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></sec><ref-list content-type="cited-references" id="cas70214-bibl-0001"><title>References</title><ref id="cas70214-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cas70214-cit-0001"><string-name name-style="western"><given-names>S.</given-names><surname>Limaye</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Deshmukh</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Rohatagi</surname></string-name>, et&#160;al., &#8220;<article-title>Usefulness of Comprehensive Genomic Profiling in Clinical Decision&#8208;Making in Oncology: A Systematic Review</article-title>,&#8221; <source>Journal of Immunotherapy and Precision Oncology</source><volume>2025</volume>, no. <issue>8</issue> (<year>2025</year>): <fpage>55</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.36401/JIPO-24-11</pub-id><pub-id pub-id-type="pmcid">PMC11728381</pub-id><pub-id pub-id-type="pmid">39811425</pub-id></mixed-citation></ref><ref id="cas70214-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cas70214-cit-0002"><string-name name-style="western"><given-names>M. Y.</given-names><surname>Tjota</surname></string-name>, <string-name name-style="western"><given-names>J. P.</given-names><surname>Segal</surname></string-name>, and <string-name name-style="western"><given-names>P.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer</article-title>,&#8221; <source>Journal of Applied Laboratory Medicine</source><volume>9</volume> (<year>2024</year>): <fpage>76</fpage>&#8211;<lpage>91</lpage>, <pub-id pub-id-type="doi">10.1093/jalm/jfad091</pub-id>.<pub-id pub-id-type="pmid">38167763</pub-id></mixed-citation></ref><ref id="cas70214-bib-0003"><label>3</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0003"><article-title>&#8220;Catalogue of Somatic Mutations in Cancer,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://cancer.sanger.ac.uk" ext-link-type="uri">http://cancer.sanger.ac.uk</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0004"><label>4</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0004"><article-title>&#8220;AACR Project GENIE,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aacr.org/professionals/research/aacr-project-genie/" ext-link-type="uri">https://www.aacr.org/professionals/research/aacr&#8208;project&#8208;genie/</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cas70214-cit-0005"><string-name name-style="western"><given-names>T.</given-names><surname>Yoshida</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Yatabe</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kato</surname></string-name>, et&#160;al., &#8220;<article-title>The Evolution of Cancer Genomic Medicine in Japan and the Role of the National Cancer Center Japan</article-title>,&#8221; <source>Cancer Biology &amp; Medicine</source><volume>21</volume> (<year>2023</year>): <fpage>29</fpage>&#8211;<lpage>44</lpage>, <pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2023.0036</pub-id>.<pub-id pub-id-type="pmid">37133223</pub-id><pub-id pub-id-type="pmcid">PMC10875288</pub-id></mixed-citation></ref><ref id="cas70214-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cas70214-cit-0006"><string-name name-style="western"><given-names>A.</given-names><surname>Ohmoto</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Hayashi</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Fukada</surname></string-name>, et&#160;al., &#8220;<article-title>Druggable Gene Alterations in Japanese Patients With Rare Malignancy</article-title>,&#8221; <source>Neoplasia</source><volume>33</volume> (<year>2022</year>): <elocation-id>100834</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.neo.2022.100834</pub-id>.<pub-id pub-id-type="pmid">36088851</pub-id><pub-id pub-id-type="pmcid">PMC9471185</pub-id></mixed-citation></ref><ref id="cas70214-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cas70214-cit-0007"><string-name name-style="western"><given-names>H.</given-names><surname>Ebi</surname></string-name> and <string-name name-style="western"><given-names>H.</given-names><surname>Bando</surname></string-name>, &#8220;<article-title>Precision Oncology and the Universal Health Coverage System in Japan</article-title>,&#8221; <source>JCO Precision Oncology</source><volume>3</volume> (<year>2019</year>): <elocation-id>291</elocation-id>, <pub-id pub-id-type="doi">10.1200/PO.19.00291</pub-id>.<pub-id pub-id-type="pmcid">PMC7446489</pub-id><pub-id pub-id-type="pmid">32923862</pub-id></mixed-citation></ref><ref id="cas70214-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cas70214-cit-0008"><string-name name-style="western"><given-names>Y.</given-names><surname>Mukai</surname></string-name> and <string-name name-style="western"><given-names>H.</given-names><surname>Ueno</surname></string-name>, &#8220;<article-title>Establishment and Implementation of Cancer Genomic Medicine in Japan</article-title>,&#8221; <source>Cancer Science</source><volume>112</volume> (<year>2021</year>): <fpage>970</fpage>&#8211;<lpage>977</lpage>, <pub-id pub-id-type="doi">10.1111/cas.14754</pub-id>.<pub-id pub-id-type="pmid">33289217</pub-id><pub-id pub-id-type="pmcid">PMC7935799</pub-id></mixed-citation></ref><ref id="cas70214-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cas70214-cit-0009"><string-name name-style="western"><given-names>Y.</given-names><surname>Naito</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Aburatani</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Amano</surname></string-name>, et&#160;al., &#8220;<article-title>Clinical Practice Guidance for Next&#8208;Generation Sequencing in Cancer Diagnosis and Treatment (Edition 2.1)</article-title>,&#8221; <source>International Journal of Clinical Oncology</source><volume>26</volume> (<year>2021</year>): <fpage>233</fpage>&#8211;<lpage>283</lpage>, <pub-id pub-id-type="doi">10.1007/s10147-020-01831-6</pub-id>.<pub-id pub-id-type="pmid">33249514</pub-id><pub-id pub-id-type="pmcid">PMC7819967</pub-id></mixed-citation></ref><ref id="cas70214-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cas70214-cit-0010"><string-name name-style="western"><given-names>K.</given-names><surname>Sunami</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Ichikawa</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kubo</surname></string-name>, et&#160;al., &#8220;<article-title>Feasibility and Utility of a Panel Testing for 114 Cancer&#8208;Associated Genes in a Clinical Setting: A Hospital&#8208;Based Study</article-title>,&#8221; <source>Cancer Science</source><volume>110</volume> (<year>2019</year>): <fpage>1480</fpage>&#8211;<lpage>1490</lpage>, <pub-id pub-id-type="doi">10.1111/cas.13969</pub-id>.<pub-id pub-id-type="pmid">30742731</pub-id><pub-id pub-id-type="pmcid">PMC6447843</pub-id></mixed-citation></ref><ref id="cas70214-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cas70214-cit-0011"><string-name name-style="western"><given-names>E.</given-names><surname>Nakata</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Ennishi</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Osone</surname></string-name>, et&#160;al., &#8220;<article-title>Real&#8208;World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in Sarcoma</article-title>,&#8221; <source>Cancer Medicine</source><volume>14</volume> (<year>2025</year>): <elocation-id>e71098</elocation-id>, <pub-id pub-id-type="doi">10.1002/cam4.71098</pub-id>.<pub-id pub-id-type="pmid">40755265</pub-id><pub-id pub-id-type="pmcid">PMC12320126</pub-id></mixed-citation></ref><ref id="cas70214-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cas70214-cit-0012"><string-name name-style="western"><given-names>H.</given-names><surname>Kage</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Kohsaka</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Tatsuno</surname></string-name>, et&#160;al., &#8220;<article-title>Molecular Analysis of Non&#8208;Small Cell Lung Cancer Using a Dual&#8208;Targeted DNA and RNA Comprehensive Genomic Profiling Panel</article-title>,&#8221; <source>Respiratory Investigation</source><volume>62</volume> (<year>2024</year>): <fpage>910</fpage>&#8211;<lpage>913</lpage>, <pub-id pub-id-type="doi">10.1016/j.resinv.2024.07.018</pub-id>.<pub-id pub-id-type="pmid">39126824</pub-id></mixed-citation></ref><ref id="cas70214-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cas70214-cit-0013"><string-name name-style="western"><given-names>J.</given-names><surname>Kikuchi</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Ohhara</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Takada</surname></string-name>, et&#160;al., &#8220;<article-title>Clinical Significance of Comprehensive Genomic Profiling Tests Covered by Public Insurance in Patients With Advanced Solid Cancers in Hokkaido, Japan</article-title>,&#8221; <source>Japanese Journal of Clinical Oncology</source><volume>51</volume> (<year>2021</year>): <fpage>753</fpage>&#8211;<lpage>761</lpage>, <pub-id pub-id-type="doi">10.1093/jjco/hyaa277</pub-id>.<pub-id pub-id-type="pmid">33532831</pub-id></mixed-citation></ref><ref id="cas70214-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cas70214-cit-0014"><string-name name-style="western"><given-names>H.</given-names><surname>Kage</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Shinozaki&#8208;Ushiku</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Ishigaki</surname></string-name>, et&#160;al., &#8220;<article-title>Clinical Utility of Todai OncoPanel in the Setting of Approved Comprehensive Cancer Genomic Profiling Tests in Japan</article-title>,&#8221; <source>Cancer Science</source><volume>114</volume> (<year>2023</year>): <fpage>1710</fpage>&#8211;<lpage>1717</lpage>, <pub-id pub-id-type="doi">10.1111/cas.15717</pub-id>.<pub-id pub-id-type="pmid">36601953</pub-id><pub-id pub-id-type="pmcid">PMC10067384</pub-id></mixed-citation></ref><ref id="cas70214-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cas70214-cit-0015"><string-name name-style="western"><given-names>S.</given-names><surname>Kohsaka</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Tatsuno</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ueno</surname></string-name>, et&#160;al., &#8220;<article-title>Comprehensive Assay for the Molecular Profiling of Cancer by Target Enrichment From Formalin&#8208;Fixed Paraffin&#8208;Embedded Specimens</article-title>,&#8221; <source>Cancer Science</source><volume>110</volume> (<year>2019</year>): <fpage>1464</fpage>&#8211;<lpage>1479</lpage>, <pub-id pub-id-type="doi">10.1111/cas.13968</pub-id>.<pub-id pub-id-type="pmid">30737998</pub-id><pub-id pub-id-type="pmcid">PMC6447855</pub-id></mixed-citation></ref><ref id="cas70214-bib-0016"><label>16</label><mixed-citation publication-type="book" id="cas70214-cit-0016"><string-name name-style="western"><given-names>C. D. M.</given-names><surname>Fletcher</surname></string-name>, <collab collab-type="authors">World Health Organization</collab>
, and <collab collab-type="authors">International Agency for Research on Cancer</collab>
, <source>WHO Classification of Tumors of Soft Tissue and Bone</source> (<publisher-name>IARC Press</publisher-name>, <year>2013</year>).</mixed-citation></ref><ref id="cas70214-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cas70214-cit-0017"><string-name name-style="western"><given-names>F.</given-names><surname>Mertens</surname></string-name> and <string-name name-style="western"><given-names>C. R.</given-names><surname>Antonescu</surname></string-name>, Mitelman F.&#8220;<article-title>Gene Fusions in Soft Tissue Tumors: Recurrent and Overlapping Pathogenetic Themes</article-title>,&#8221; <source>Genes, Chromosomes &amp; Cancer</source><volume>55</volume> (<year>2016</year>): <fpage>291</fpage>&#8211;<lpage>310</lpage>, <pub-id pub-id-type="doi">10.1002/gcc.22335</pub-id>.<pub-id pub-id-type="pmid">26684580</pub-id><pub-id pub-id-type="pmcid">PMC5012284</pub-id></mixed-citation></ref><ref id="cas70214-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cas70214-cit-0018"><string-name name-style="western"><given-names>M. M.</given-names><surname>Gounder</surname></string-name>, <string-name name-style="western"><given-names>N. P.</given-names><surname>Agaram</surname></string-name>, <string-name name-style="western"><given-names>S. E.</given-names><surname>Trabucco</surname></string-name>, et&#160;al., &#8220;<article-title>Clinical Genomic Profiling in the Management of Patients With Soft Tissue and Bone Sarcoma</article-title>,&#8221; <source>Nature Communications</source><volume>13</volume> (<year>2022</year>): <elocation-id>3406</elocation-id>, <pub-id pub-id-type="doi">10.1038/s41467-022-30496-0</pub-id>.<pub-id pub-id-type="pmcid">PMC9200814</pub-id><pub-id pub-id-type="pmid">35705558</pub-id></mixed-citation></ref><ref id="cas70214-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cas70214-cit-0019"><string-name name-style="western"><given-names>S.</given-names><surname>Boddu</surname></string-name>, <string-name name-style="western"><given-names>C. M.</given-names><surname>Walko</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bienasz</surname></string-name>, et&#160;al., &#8220;<article-title>Clinical Utility of Genomic Profiling in the Treatment of Advanced Sarcomas: A Single&#8208;Center Experience</article-title>,&#8221; <source>JCO Precision Oncology</source><volume>2</volume> (<year>2018</year>): <fpage>1</fpage>&#8211;<lpage>8</lpage>, <pub-id pub-id-type="doi">10.1200/PO.18.00096</pub-id>.<pub-id pub-id-type="pmid">35135155</pub-id></mixed-citation></ref><ref id="cas70214-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cas70214-cit-0020"><string-name name-style="western"><given-names>C. A.</given-names><surname>Gusho</surname></string-name>, <string-name name-style="western"><given-names>M. C.</given-names><surname>Weiss</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Lee</surname></string-name>, et&#160;al., &#8220;<article-title>The Clinical Utility of Next&#8208;Generation Sequencing for Bone and Soft Tissue Sarcoma</article-title>,&#8221; <source>Acta Oncologica</source><volume>61</volume> (<year>2022</year>): <fpage>38</fpage>&#8211;<lpage>44</lpage>, <pub-id pub-id-type="doi">10.1080/0284186X.2021.1992009</pub-id>.<pub-id pub-id-type="pmid">34686105</pub-id></mixed-citation></ref><ref id="cas70214-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cas70214-cit-0021"><string-name name-style="western"><given-names>R.</given-names><surname>Groisberg</surname></string-name>, <string-name name-style="western"><given-names>D. S.</given-names><surname>Hong</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Holla</surname></string-name>, et&#160;al., &#8220;<article-title>Clinical Genomic Profiling to Identify Actionable Alterations for Investigational Therapies in Patients With Diverse Sarcomas</article-title>,&#8221; <source>Oncotarget</source><volume>8</volume> (<year>2017</year>): <fpage>39254</fpage>&#8211;<lpage>39267</lpage>, <pub-id pub-id-type="doi">10.18632/oncotarget.16845</pub-id>.<pub-id pub-id-type="pmid">28424409</pub-id><pub-id pub-id-type="pmcid">PMC5503611</pub-id></mixed-citation></ref><ref id="cas70214-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cas70214-cit-0022"><string-name name-style="western"><given-names>L. R.</given-names><surname>Massoth</surname></string-name>, <string-name name-style="western"><given-names>Y. P.</given-names><surname>Hung</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Ferry</surname></string-name>, et&#160;al., &#8220;<article-title>Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct From Follicular Dendritic Cell Sarcoma</article-title>,&#8221; <source>Oncologist</source><volume>26</volume> (<year>2021</year>): <fpage>e1263</fpage>&#8211;<lpage>e1272</lpage>, <pub-id pub-id-type="doi">10.1002/onco.13801</pub-id>.<pub-id pub-id-type="pmid">33904632</pub-id><pub-id pub-id-type="pmcid">PMC8265357</pub-id></mixed-citation></ref><ref id="cas70214-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cas70214-cit-0023"><string-name name-style="western"><given-names>R.</given-names><surname>Lopes&#8208;Br&#225;s</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Lopez&#8208;Presa</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Esperan&#231;a&#8208;Martins</surname></string-name>, et&#160;al., &#8220;<article-title>Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>23</volume> (<year>2022</year>): <elocation-id>14227</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms232214227</pub-id>.<pub-id pub-id-type="pmid">36430703</pub-id><pub-id pub-id-type="pmcid">PMC9693140</pub-id></mixed-citation></ref><ref id="cas70214-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cas70214-cit-0024"><string-name name-style="western"><given-names>L.</given-names><surname>Xu</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Xie</surname></string-name>, <string-name name-style="western"><given-names>X.</given-names><surname>Shi</surname></string-name>, et&#160;al., &#8220;<article-title>Potential Application of Genomic Profiling for the Diagnosis and Treatment of Patients With Sarcoma</article-title>,&#8221; <source>Oncology Letters</source><volume>21</volume> (<year>2021</year>): <elocation-id>353</elocation-id>, <pub-id pub-id-type="doi">10.3892/ol.2021.12614</pub-id>.<pub-id pub-id-type="pmid">33747210</pub-id><pub-id pub-id-type="pmcid">PMC7967939</pub-id></mixed-citation></ref><ref id="cas70214-bib-0025"><label>25</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0025"><article-title>&#8220;ClinVar,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0026"><article-title>&#8220;Ambry Genetics Database,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ambrygen.com/" ext-link-type="uri">https://www.ambrygen.com/</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0027"><label>27</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0027"><article-title>&#8220;COSMIC Fusions,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cancer.sanger.ac.uk/cosmic/fusion" ext-link-type="uri">https://cancer.sanger.ac.uk/cosmic/fusion</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0028"><label>28</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0028"><article-title>&#8220;FusionGDB,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ccsm.uth.edu/FusionGDB/index.html" ext-link-type="uri">https://ccsm.uth.edu/FusionGDB/index.html</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0029"><label>29</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0029"><article-title>&#8220;TCGA Fusion Gene Database,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.tumorfusions.org" ext-link-type="uri">https://www.tumorfusions.org</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0030"><label>30</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0030"><article-title>&#8220;Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://mitelmandatabase.isb-cgc.org" ext-link-type="uri">https://mitelmandatabase.isb&#8208;cgc.org</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0031"><label>31</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0031"><article-title>&#8220;Fusion Profiling Interactive Analysis,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioinfo-sysu.com/fpia/#update" ext-link-type="uri">https://bioinfo&#8208;sysu.com/fpia/#update</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="cas70214-cit-0032"><article-title>&#8220;PubMed,&#8221;</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/</ext-link>.</mixed-citation></ref><ref id="cas70214-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cas70214-cit-0033"><string-name name-style="western"><given-names>T. S. K.</given-names><surname>Mok</surname></string-name>, <string-name name-style="western"><given-names>Y. L.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Kudaba</surname></string-name>, et&#160;al., &#8220;<article-title>Pembrolizumab Versus Chemotherapy for Previously Untreated, PD&#8208;L1&#8208;Expressing, Locally Advanced or Metastatic Non&#8208;Small&#8208;Cell Lung Cancer (KEYNOTE&#8208;042): A Randomised, Open&#8208;Label, Controlled, Phase 3 Trial</article-title>,&#8221; <source>Lancet</source><volume>393</volume> (<year>2019</year>): <fpage>1819</fpage>&#8211;<lpage>1830</lpage>, <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32409-7</pub-id>.<pub-id pub-id-type="pmid">30955977</pub-id></mixed-citation></ref><ref id="cas70214-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cas70214-cit-0034"><string-name name-style="western"><given-names>S.</given-names><surname>Tadaka</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Hishinuma</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Komaki</surname></string-name>, et&#160;al., &#8220;<article-title>jMorp Updates in 2020: Large Enhancement of Multi&#8208;Omics Data Resources on the General Japanese Population</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>49</volume> (<year>2021</year>): <fpage>D536</fpage>&#8211;<lpage>D544</lpage>, <pub-id pub-id-type="doi">10.1093/nar/gkaa1034</pub-id>.<pub-id pub-id-type="pmid">33179747</pub-id><pub-id pub-id-type="pmcid">PMC7779038</pub-id></mixed-citation></ref><ref id="cas70214-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cas70214-cit-0035"><string-name name-style="western"><given-names>S.</given-names><surname>Tadaka</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Katsuoka</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ueki</surname></string-name>, et&#160;al., &#8220;<article-title>3.5KJPNv2: An Allele Frequency Panel of 3552 Japanese Individuals Including the X Chromosome</article-title>,&#8221; <source>Human Genome Variation</source><volume>6</volume> (<year>2019</year>): <fpage>28</fpage>, <pub-id pub-id-type="doi">10.1038/s41439-019-0059-5</pub-id>.<pub-id pub-id-type="pmid">31240104</pub-id><pub-id pub-id-type="pmcid">PMC6581902</pub-id></mixed-citation></ref><ref id="cas70214-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cas70214-cit-0036"><string-name name-style="western"><given-names>S.</given-names><surname>Richards</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Aziz</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Bale</surname></string-name>, et&#160;al., &#8220;<article-title>Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>,&#8221; <source>Genetics in Medicine</source><volume>17</volume> (<year>2015</year>): <fpage>405</fpage>&#8211;<lpage>424</lpage>, <pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id>.<pub-id pub-id-type="pmid">25741868</pub-id><pub-id pub-id-type="pmcid">PMC4544753</pub-id></mixed-citation></ref><ref id="cas70214-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cas70214-cit-0037"><string-name name-style="western"><given-names>J.</given-names><surname>Bordeaux</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Blitzblau</surname></string-name>, <string-name name-style="western"><given-names>S. Z.</given-names><surname>Aasi</surname></string-name>, et&#160;al., &#8220;<article-title>Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines in Oncology</article-title>,&#8221; <source>Journal of the National Comprehensive Cancer Network</source><volume>23</volume> (<year>2025</year>): <elocation-id>e250001</elocation-id>, <pub-id pub-id-type="doi">10.6004/jnccn.2025.0001</pub-id>.<pub-id pub-id-type="pmid">39819674</pub-id></mixed-citation></ref><ref id="cas70214-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cas70214-cit-0038"><string-name name-style="western"><given-names>A. J.</given-names><surname>Hayes</surname></string-name>, <string-name name-style="western"><given-names>I. F.</given-names><surname>Nixon</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Strauss</surname></string-name>, et&#160;al., &#8220;<article-title>UK Guidelines for the Management of Soft Tissue Sarcomas</article-title>,&#8221; <source>British Journal of Cancer</source><volume>132</volume> (<year>2025</year>): <fpage>11</fpage>&#8211;<lpage>31</lpage>, <pub-id pub-id-type="doi">10.1038/s41416-024-02674-y</pub-id>.<pub-id pub-id-type="pmid">38734790</pub-id><pub-id pub-id-type="pmcid">PMC11724041</pub-id></mixed-citation></ref><ref id="cas70214-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cas70214-cit-0039"><string-name name-style="western"><given-names>M.</given-names><surname>Tanaka</surname></string-name> and <string-name name-style="western"><given-names>T.</given-names><surname>Nakamura</surname></string-name>, &#8220;<article-title>Modeling Fusion Gene&#8208;Associated Sarcoma: Advantages for Understanding Sarcoma Biology and Pathology</article-title>,&#8221; <source>Pathology International</source><volume>71</volume> (<year>2021</year>): <fpage>643</fpage>&#8211;<lpage>654</lpage>, <pub-id pub-id-type="doi">10.1111/pin.13142</pub-id>.<pub-id pub-id-type="pmid">34265156</pub-id></mixed-citation></ref><ref id="cas70214-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cas70214-cit-0040"><string-name name-style="western"><given-names>X. Q.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Goytain</surname></string-name>, <string-name name-style="western"><given-names>B. C.</given-names><surname>Dickson</surname></string-name>, and <string-name name-style="western"><given-names>T. O.</given-names><surname>Nielsen</surname></string-name>, &#8220;<article-title>Advances in Sarcoma Molecular Diagnostics</article-title>,&#8221; <source>Genes, Chromosomes &amp; Cancer</source><volume>61</volume> (<year>2022</year>): <fpage>332</fpage>&#8211;<lpage>345</lpage>, <pub-id pub-id-type="doi">10.1002/gcc.23025</pub-id>.<pub-id pub-id-type="pmid">35064596</pub-id></mixed-citation></ref><ref id="cas70214-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="cas70214-cit-0041"><string-name name-style="western"><given-names>R.</given-names><surname>Colomer</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Mondejar</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Romero&#8208;Laorden</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Alfranca</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Sanchez&#8208;Madrid</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Quintela&#8208;Fandino</surname></string-name>, &#8220;<article-title>When Should We Order a Next Generation Sequencing Test in a Patient With Cancer?</article-title>,&#8221; <source>E Clinical Medicine</source><volume>25</volume> (<year>2020</year>): <elocation-id>100487</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100487</pub-id>.<pub-id pub-id-type="pmcid">PMC7397394</pub-id><pub-id pub-id-type="pmid">32775973</pub-id></mixed-citation></ref><ref id="cas70214-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="cas70214-cit-0042"><string-name name-style="western"><given-names>E.</given-names><surname>Nakata</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Osone</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Ogawa</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Taguchi</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Hattori</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Kohsaka</surname></string-name>, &#8220;<article-title>Prevalence of Neurotrophic Tropomyosin Receptor Kinase (NTRK) Fusion Gene Positivity in Patients With Solid Tumors in Japan</article-title>,&#8221; <source>Cancer Medicine</source><volume>13</volume> (<year>2024</year>): <elocation-id>e7351</elocation-id>, <pub-id pub-id-type="doi">10.1002/cam4.7351</pub-id>.<pub-id pub-id-type="pmid">38925616</pub-id><pub-id pub-id-type="pmcid">PMC11199329</pub-id></mixed-citation></ref><ref id="cas70214-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="cas70214-cit-0043"><string-name name-style="western"><given-names>N.</given-names><surname>Ebrahimi</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Fardi</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Ghaderi</surname></string-name>, et&#160;al., &#8220;<article-title>Receptor Tyrosine Kinase Inhibitors in Cancer</article-title>,&#8221; <source>Cellular and Molecular Life Sciences</source><volume>80</volume> (<year>2023</year>): <fpage>104</fpage>, <pub-id pub-id-type="doi">10.1007/s00018-023-04729-4</pub-id>.<pub-id pub-id-type="pmid">36947256</pub-id><pub-id pub-id-type="pmcid">PMC11073124</pub-id></mixed-citation></ref><ref id="cas70214-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="cas70214-cit-0044"><string-name name-style="western"><given-names>D.</given-names><surname>Mandelker</surname></string-name> and <string-name name-style="western"><given-names>O.</given-names><surname>Ceyhan&#8208;Birsoy</surname></string-name>, &#8220;<article-title>Evolving Significance of Tumor&#8208;Normal Sequencing in Cancer Care</article-title>,&#8221; <source>Trends Cancer</source><volume>6</volume> (<year>2020</year>): <fpage>31</fpage>&#8211;<lpage>39</lpage>, <pub-id pub-id-type="doi">10.1016/j.trecan.2019.11.006</pub-id>.<pub-id pub-id-type="pmid">31952779</pub-id><pub-id pub-id-type="pmcid">PMC8923150</pub-id></mixed-citation></ref><ref id="cas70214-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="cas70214-cit-0045"><string-name name-style="western"><given-names>J.</given-names><surname>Vagher</surname></string-name>, <string-name name-style="western"><given-names>C. J.</given-names><surname>Mehrhoff</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Florou</surname></string-name>, and <string-name name-style="western"><given-names>L. D.</given-names><surname>Maese</surname></string-name>, &#8220;<article-title>Genetic Predisposition to Sarcoma: What Should Clinicians Know?</article-title>,&#8221; <source>Current Treatment Options in Oncology</source><volume>25</volume> (<year>2024</year>): <fpage>769</fpage>&#8211;<lpage>783</lpage>, <pub-id pub-id-type="doi">10.1007/s11864-024-01192-6</pub-id>.<pub-id pub-id-type="pmid">38713268</pub-id></mixed-citation></ref><ref id="cas70214-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="cas70214-cit-0046"><string-name name-style="western"><given-names>H.</given-names><surname>Ida</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Koyama</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Mizuno</surname></string-name>, et&#160;al., &#8220;<article-title>Clinical Utility of Comprehensive Genomic Profiling Tests for Advanced or Metastatic Solid Tumor in Clinical Practice</article-title>,&#8221; <source>Cancer Science</source><volume>113</volume> (<year>2022</year>): <fpage>4300</fpage>&#8211;<lpage>4310</lpage>, <pub-id pub-id-type="doi">10.1111/cas.15586</pub-id>.<pub-id pub-id-type="pmid">36106376</pub-id><pub-id pub-id-type="pmcid">PMC9746060</pub-id></mixed-citation></ref><ref id="cas70214-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="cas70214-cit-0047"><string-name name-style="western"><given-names>I.</given-names><surname>Fukada</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mori</surname></string-name>, <string-name name-style="western"><given-names>N.</given-names><surname>Hayashi</surname></string-name>, et&#160;al., &#8220;<article-title>Prognostic Impact of Cancer Genomic Profile Testing for Advanced or Metastatic Solid Tumors in Clinical Practice</article-title>,&#8221; <source>Cancer Science</source><volume>114</volume> (<year>2023</year>): <fpage>4632</fpage>&#8211;<lpage>4642</lpage>, <pub-id pub-id-type="doi">10.1111/cas.15993</pub-id>.<pub-id pub-id-type="pmid">37858313</pub-id><pub-id pub-id-type="pmcid">PMC10728004</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>